The Safety and efficacy of Autologous Natural Killer cell infusions for the Treatment of Malignant
Lymphoma : Phase ll trial (MKBIO.2016)
50 patients with Relapsed or refractory malignant lyphoma previously untreated NK/T cell lymphoma
NK cell infusion Autologous activated NK cell
2 x 10 cells/100 ml lV x 5 times
between 1st mar. 2006 and 31 Dec. 2006
Intermediate Tumor Response Assessment
Power CR reached
QOL (quality of life)
Reduced non-hematologic complications Side effects
"All of patients (n=50) who received NK cell therapy showed complete response in clinical trial ll"
Lung cancer - Clinical Trial
A Trial of Autologous Ex vivo-expanded NK Cell-enriched Lymphocytes with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer as Second - or Third-line Treatment: Phase lla Study
Patients no (%) (n=19)
Complete response (CR)
Partial response (PR)
Stable disease (SD)
Progressive disease (PD)
Autologous NKL production and co-administration with docetaxel were feasible without further toxicity or complication for secondary or tertiary anticancer treatments. Partial response patients rate and pathogen-free survixal were incresed three fold more than control who did not received any treatments on reports.
Liver cancer - Clinical Trial
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma : A preliminary clinocal study
The percentage of patients who experienced partial response, disease stabilization, and disease progression at 3 months after treatment was 18.8%, 50.0% and 31.2%, respectively. The PFS from treatment was significantly higher among patients who received more than four courses of NK cell transfusions than those who received less than four courses.
NK cell immunotherapy is safe. can improve the immune function of patients with liver cancer, and may even reduce the rate of tumor metastasis and recurrence.
Breast cancer - Clinical Trial
After total mastectomy, local recurrence of breast cancer and multiple hepatic metastases were observed
A patient who underwent surgery for a breast cancer with multiple metastasis. After NK therapy with anticancer agents, the proportion of MK cells in the blood was more than tripled, from 8.7% before the treatment, to 27.6% after 10 times of administration. With this increase, NK activity was also roughly doubled. Highly active NK cell therapy that enables the maintenance of a high level of body`s immunity is very useful when it is used with anticancer agents.
Colorectal Cancer (with metastasis) - Clinical Trial
After the surgeries for colorectal cancer and lung metastasis, the third metastasis was detected in the liverm, but could not be treated with surgery
After 5-times NK cell therapy, liver tumor largely disappeared and lymph node metastasis became smaller in a patient who had colorectal cancer with lung and liver metastasis.